Genervon Biopharmaceuticals LLC |
||
January 28, 2013 Issue |
||
The Most Powerful Name In Corporate News and Information |
||
Genervon Biopharmaceuticals is Well Positioned for GrowthTwo ongoing CNS Phase 2 Clinical Trials and an additional pipeline of ten Phase 2 ready indications. Its novel first-in-class, human endogenous embryonic stage master regulator peptide drugs are for the nervous system. |
||
Winston Ko
About Genervon Biopharmaceuticals LLC Genervon has discovered a novel, endogenous, embryonic stage family of nine, first-in-class, human master regulators peptide drugs of the nervous system and has 46 Composition of Matter and Use patents. One of the master regulators, GM600, has two ongoing Phase 2 clinical trials and an additional pipeline of ten indications Phase 2 ready.
Genervon scientists have confirmed that one of the master regulator peptides, GM600, regulates over 4,000 genes. They have mapped out the ALS mechanisms of action (MOA’s). GM600 controls and modulates over thirty known and significant ALS genes with positive effects, through at least eight pathways, potentially more, concurrently, systemically and dynamically, and up to twenty-two biological functions, including neurogenesis, neural development, neuronal signaling, neural transport, etc. Their master regulator peptide drug modulates not one but more than thirty ALS mutant genes with, not a cocktail of drugs, but one peptide drug.
GM604 also proved to be very effective in the disease modification of ALS animal models with mutant SOD1 genes and Wobbler mice models. It led to improved clinical scores in SOD1 mice. Moreover, GM604 delayed the onset of ALS symptoms by 27%, extended life by 30% and delayed the median clinical score deterioration time in ALS mice by 41%.
GM604 also provided neuroprotection against soluble inflammatory factors from ALS human patients' Cerebral Spinal Fluid (CSF) in vitro by 175%.
GM604 dramatically increased the survival life span by 500% (6 fold from 7-14 weeks to 55-65 weeks) and increased preservation of motoneurons by 160% (2.6 fold) in a Wobbler Mice Model for motoneuron diseases similar to ALS.
The discovery of endogenous, embryonic stage, human master regulators is changing the drug development paradigm from hitting a single gene/pathway to a comprehensive and dynamic, multi-factorial approach to treat complex Central Nervous System (CNS) disorders and systemic diseases. Genervon is at the forefront of a drug development paradigm shift that is beginning to be appreciated.
Genervon Biopharmaceuticals, LLC is an innovative clinical stage biopharmaceutical company providing breakthrough biological drugs for unmet medical needs. |
Central and Peripheral Nervous Systems
Genervon Biopharmaceuticals LLC
1055 E. Colorado Blvd., Fifth Floor
|
|
Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – January 28, 2013
CEOCFO:
What is so difficult about it? Why is it in that category?
CEOCFO: What is your approach? How do you look at it, and how have you come up with something that is different? Mr. Ko: We had to develop two novel proprietary technology platforms. The first is Protein Bands Selection by Function to find the fetal signal regulators. The second is In Silico Analysis to find active sites, e.g., we can identify the active sites of the Epogen. We also had to become experts in embryonic development, biologic systems, signaling and master regulator systems, genetics, genomics and mechanisms of action in multi-factorial processes.
CEOCFO:
What have you developed so far? Where are you in the research?
CEOCFO:
What have you done with what you have found so far?
Spinal Cord Injury Studies: decreased lesion volume by 53%. Sciatic Nerve Gap Studies: increased motoneurons crossing 8mm gap by 150%. Wobbler Mice Studies (motoneurons degeneration model): increased survival life span by 500% and increase preservation of motor neurons by 160%. ALS SOD1 Mice Studies: delayed median clinical score by 41%, delayed symptoms by 27% and delayed death by 30%. Multiple Sclerosis studies: improved clinical score by 270%, reduced lesions in the brain by 68% and the spinal cord by 67%. Parkinson’s Disease studies: increased monoamines and metabolite levels including dopamine, DOPAC and HVA in the brain by 600%, improved movements by 250%, improved behavioral score by 250% and preserved neurons in Substantia Nigra by 300%. Stroke Studies: reduced infarct volume by 56% (PMCAO in rats) and 73% (MCAO in mice); increased neurogenesis by 75%; decreased neurological deficit by 52%; reduced apoptosis by 65% and reduced inflammation by 75%. Our Stroke and PD clinical trials are in Phase 2 now.
The European Patent Office notified Genervon less than a month ago of its intention to grant a European patent on Methods of Treating Neuronal Disorders using MNTF peptides and analogs thereof. That will bring the portfolio of Genervon’s Composition of Matters and Use patents to 46.
CEOCFO:
Has your approach to find master regulators been tried in the past or is the
whole idea itself novel to Genervon?
CEOCFO:
Have the medical communities caught up with what you figured out at
Genervon?
CEOCFO:
What about funding? It is always difficult, but particularly when you are
taking more of a maverick approach. How far can your current funding take
Genervon Biopharmaceuticals?
CEOCFO:
How do you deal, on a personal level, with the frustration of knowing that
you have something that could really be game changing, and life changing,
but it is such an arduous process to get it into use and for it to be
accepted in any form?
CEOCFO:
What are your next steps the next year or so?
CEOCFO:
Why should investors and people in the business community be paying
attention to Genervon?
CEOCFO:
Do you have any final thoughts?
CEOCFO:
We have many readers that follow the bio industry, because we talk to many
companies in your industry. It is definitely an area that people take a look
at to know what is going on. |
||
“Genervon has discovered a novel, endogenous embryonic stage family of nine, first-in-class human master regulators peptide drug of the nervous system and has 46 Composition of Matter and Use patents. One of the master regulators, GM600, has two ongoing Phase 2 clinical trials and an additional pipeline of ten indications Phase 2 ready. Only CEOs have the vision, courage and authority to be an internal champion to implement paradigm shifting technology.”- Winston Ko
“Only CEOs have the vision, courage and authority to be an internal corporate champion to implement paradigm shifting technology.” - Winston Ko |
||
|
||
Central Nervous Systems, CNS, Drugs, Genervon Biopharmaceuticals LLC, CEO Interviews 2013, human endogenous embryonic stage master regulator peptide drugs for the nervous system, Drug Development Companies, Recent CEO Interviews, Drug Development Stock, Healthcare Stocks, multi-factorial approach to treat complex Central Nervous System (CNS) disorders and systemic diseases, Protein Bands Selection by Function to find the fetal signal regulators, In Silico Analysis to find active sites, identifying the active sites of the Epogen, embryonic development, biologic systems, signaling and master regulator systems, genetics, genomics, mechanisms of action in multi-factorial processes, Genervon Biopharmaceuticals LLC, Press Releases, News, Companies looking for venture capital, Angel Investors, private companies looking for investors, healthcare companies seeking investors, drug development companies needing investment capital |
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.